Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery

13Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

An anti-glucocorticoid induced TNF receptor (GITR) agonistic antibody (Ab) induces an antitumor immunity with both stimulation of effector T cells and inhibition of regulatory T cell activity. To enhance GITR Ab-mediated tumor immunity, we focused on the intratumoral route, since a tumor-localized high concentration of Ab would confer activation of only tumor-infiltrating T cells. First, in a murine colon cancer model, we showed that the intratumoral delivery of Ab significantly increased the number of effector T cells infiltrated into tumors, and suppressed tumor growth more effectively than the intraperitoneal and intravenous injections did. Then, we found that the injection of Ab into the peritumoral area induced a systemic antitumor immunity at a similar level to the intratumoral injection. Therefore, we hypothesized that the transfer of locally administrated Ab into tumor-draining lymph nodes (TDLNs) plays an important role in inducing an effective immunity. In fact, intratumorally or peritumorally injected Ab was detected in TDLNs, and resection of Ab-injected TDLNs significantly reduced GITR Ab-mediated systemic tumor immunity. Intratumoral injection showed less number of auto-reactive T cells in the spleen than the intraperitoneal injection did. Intratumoral delivery of GITR Ab is a promising approach to induce an effective immunity compared to the systemic delivery.

References Powered by Scopus

Improved survival with ipilimumab in patients with metastatic melanoma

12592Citations
N/AReaders
Get full text

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

10420Citations
N/AReaders
Get full text

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

6573Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immunosurveillance and immunoediting of lung cancer: Current perspectives and challenges

66Citations
N/AReaders
Get full text

Co-stimulatory receptors in cancers and their implications for cancer immunotherapy

43Citations
N/AReaders
Get full text

New emerging targets in cancer immunotherapy: The role of GITR

39Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Narumi, K., Miyakawa, R., Shibasaki, C., Henmi, M., Mizoguchi, Y., Ueda, R., … Aoki, K. (2019). Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-41724-x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

63%

Researcher 5

31%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

41%

Biochemistry, Genetics and Molecular Bi... 4

24%

Pharmacology, Toxicology and Pharmaceut... 3

18%

Immunology and Microbiology 3

18%

Save time finding and organizing research with Mendeley

Sign up for free